Aphaia Pharma US LLC

Quick facts

Phase 2 pipeline

• APH-012P · Diabetes
  APH-012P is a small molecule that targets the SGLT2 receptor.
• APHD-002 · Diabetes
  APHD-002 is a small molecule that targets the SGLT2 receptor.
• APHD-012 · Diabetes
  APHD-012 is a small molecule that targets the SGLT2 receptor.
• APHD-012P
• APHP-002 · Diabetes
  APHP-002 is a small molecule that targets the SGLT2 receptor.
• APHP-012

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Aphaia Pharma US LLC portfolio CI brief
• Aphaia Pharma US LLC pipeline updates RSS